Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT-LTBI: Daily rifampicin + isoniazid vs weekly rifapentine + isoniazid for latent tuberculosis infection
2013-000750-21Phase 4Completed
- Sponsor
- University College London
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in latent tuberculosis infection (LTBI) comparing Daily rifampicin + isoniazid with Weekly rifapentine + isoniazid (2 arms). Primary endpoint: Treatment completion by self-report, pill count, and urine isoniazid metabolite testing. Started Jan 2014; status: completed.
02
Drugs
rifapentineisoniazid + rifampicinisoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2013-000750-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000750-21.